brepocitinib vs Girocitinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: TYK2/JAK1 · full Psoriasis pipeline

brepocitinib · Lisraya

Marketed by Roivant Sciences Ltd. and partners

Phase 2 in Psoriasissmall molecule
Partial signal

NCT02969018 · Phase 2 · completed

The trial randomized 212 participants to seven blinded PF-06700841 regimens or matching placebo, with PASI score change at week 12 as the clinical primary endpoint. Five of seven PF-06700841 regimens significantly improved PASI versus placebo, but two comparisons were not statistically significant, making the overall primary result mixed rather than consistently positive.

Reported efficacy

Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12 (Baseline (Day 1 pre-dose), Week 12): Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12 (Baseline (Day 1 pre-dose), Week 12): PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD -15.85 units on a scale (95% CI -18.31 to -13.39) | PF-06700841 60 mg QD Followed by 10 mg QD -10.56 units on a scale (95% CI -12.96 to -8.16) | PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW) -14.28 units on a scale (95% CI -16.75 to -11.81) | PF-06700841 60 mg QD Followed by Placebo -10.14 units on a scale (95% CI -12.62 to -7.66) | PF-06700841 30 mg QD -17.28 units on a scale (95% CI -19.55 to -15.02) | PF-06700841 30 mg QD Followed by 10 mg QD -13.27 units on a scale (95% CI -15.78 to -10.76) | PF-06700841 30 mg QD Followed by 100 mg QW -11.88 units on a scale (95% CI -14.16 to -9.59) vs Placebo -7.21 units on a scale (95% CI -9.96 to -4.46) (mixed)

Result source: NCT02969018

Girocitinib

Developed by Hangzhou Highlightll Pharmaceutical

small molecule
Partial signal

NCT05772520 · Phase 2 · completed

The study was randomized, triple-blind, and placebo-controlled, but it had small dose-specific groups, including 14 participants in the placebo arm. PASI-75 is a clinical endpoint; although the reported response counts favored the 20-mg and 40-mg doses, statistical significance for the primary comparison was not reported.

No aligned efficacy figure on record for this race.

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointbrepocitinibGirocitinib
PASI 7560% vs 13%+47 vs placebo60 mg Once Daily (QD) Followed by 30 mg QD · wk 12 · n 25NCT02969018
125 other results
  • 24.1% vs 13% 60 mg QD Followed by 10 mg QD · wk 12 · n 29 · Phase 2 · secondary NCT02969018
  • 57.7% vs 13% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 12 · n 26 · Phase 2 · secondary NCT02969018
  • 24% vs 13% 60 mg QD Followed by Placebo · wk 12 · n 25 · Phase 2 · secondary NCT02969018
  • 48% vs 13% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 10 · n 25 · Phase 2 · secondary NCT02969018
  • 24.1% vs 13% 60 mg QD Followed by 10 mg QD · wk 10 · n 29 · Phase 2 · secondary NCT02969018
  • 61.5% vs 13% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 10 · n 26 · Phase 2 · secondary NCT02969018
  • 32% vs 13% 60 mg QD Followed by Placebo · wk 10 · n 25 · Phase 2 · secondary NCT02969018
  • 48% vs 8.7% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 14 · n 25 · Phase 2 · secondary NCT02969018
  • 17.2% vs 8.7% 60 mg QD Followed by 10 mg QD · wk 14 · n 29 · Phase 2 · secondary NCT02969018
  • 34.6% vs 8.7% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 14 · n 26 · Phase 2 · secondary NCT02969018
  • 16% vs 8.7% 60 mg QD Followed by Placebo · wk 14 · n 25 · Phase 2 · secondary NCT02969018
  • 60% vs 8.7% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 8 · n 25 · Phase 2 · secondary NCT02969018
  • 37.9% vs 8.7% 60 mg QD Followed by 10 mg QD · wk 8 · n 29 · Phase 2 · secondary NCT02969018
  • 65.4% vs 8.7% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 8 · n 26 · Phase 2 · secondary NCT02969018
  • 32% vs 8.7% 60 mg QD Followed by Placebo · wk 8 · n 25 · Phase 2 · secondary NCT02969018
  • 36% vs 8.7% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 16 · n 25 · Phase 2 · secondary NCT02969018
  • 10.3% vs 8.7% 60 mg QD Followed by 10 mg QD · wk 16 · n 29 · Phase 2 · secondary NCT02969018
  • 30.8% vs 8.7% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 16 · n 26 · Phase 2 · secondary NCT02969018
  • 20% vs 8.7% 60 mg QD Followed by Placebo · wk 16 · n 25 · Phase 2 · secondary NCT02969018
  • 44% vs 8.7% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 6 · n 25 · Phase 2 · secondary NCT02969018
  • 41.4% vs 8.7% 60 mg QD Followed by 10 mg QD · wk 6 · n 29 · Phase 2 · secondary NCT02969018
  • 65.4% vs 8.7% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 6 · n 26 · Phase 2 · secondary NCT02969018
  • 36% vs 8.7% 60 mg QD Followed by Placebo · wk 6 · n 25 · Phase 2 · secondary NCT02969018
  • 24% vs 0% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 4 · n 25 · Phase 2 · secondary NCT02969018
  • 41.4% vs 0% 60 mg QD Followed by 10 mg QD · wk 4 · n 29 · Phase 2 · secondary NCT02969018
  • 61.5% vs 0% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 4 · n 26 · Phase 2 · secondary NCT02969018
  • 36% vs 0% 60 mg QD Followed by Placebo · wk 4 · n 25 · Phase 2 · secondary NCT02969018
  • 8% vs 0% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 2 · n 25 · Phase 2 · secondary NCT02969018
  • 13.8% vs 0% 60 mg QD Followed by 10 mg QD · wk 2 · n 29 · Phase 2 · secondary NCT02969018
  • 26.9% vs 0% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 2 · n 26 · Phase 2 · secondary NCT02969018
  • 12% vs 0% 60 mg QD Followed by Placebo · wk 2 · n 25 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 1 · n 25 · Phase 2 · secondary NCT02969018
  • 6.9% vs 0% 60 mg QD Followed by 10 mg QD · wk 1 · n 29 · Phase 2 · secondary NCT02969018
  • 7.7% vs 0% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 1 · n 26 · Phase 2 · secondary NCT02969018
  • 4% vs 0% 60 mg QD Followed by Placebo · wk 1 · n 25 · Phase 2 · secondary NCT02969018
  • 86.2% vs 13% 30 mg QD · wk 12 · n 29 · Phase 2 · secondary NCT02969018
  • 24% vs 13% 30 mg QD Followed by 10 mg QD · wk 12 · n 25 · Phase 2 · secondary NCT02969018
  • 36.7% vs 13% 30 mg QD Followed by 100 mg QW · wk 12 · n 30 · Phase 2 · secondary NCT02969018
  • 72.4% vs 13% 30 mg QD · wk 10 · n 29 · Phase 2 · secondary NCT02969018
  • 28% vs 13% 30 mg QD Followed by 10 mg QD · wk 10 · n 25 · Phase 2 · secondary NCT02969018
  • 46.7% vs 13% 30 mg QD Followed by 100 mg QW · wk 10 · n 30 · Phase 2 · secondary NCT02969018
  • 75.9% vs 8.7% 30 mg QD · wk 14 · n 29 · Phase 2 · secondary NCT02969018
  • 16% vs 8.7% 30 mg QD Followed by 10 mg QD · wk 14 · n 25 · Phase 2 · secondary NCT02969018
  • 16.7% vs 8.7% 30 mg QD Followed by 100 mg QW · wk 14 · n 30 · Phase 2 · secondary NCT02969018
  • 65.5% vs 8.7% 30 mg QD · wk 8 · n 29 · Phase 2 · secondary NCT02969018
  • 20% vs 8.7% 30 mg QD Followed by 10 mg QD · wk 8 · n 25 · Phase 2 · secondary NCT02969018
  • 40% vs 8.7% 30 mg QD Followed by 100 mg QW · wk 8 · n 30 · Phase 2 · secondary NCT02969018
  • 58.6% vs 8.7% 30 mg QD · wk 16 · n 29 · Phase 2 · secondary NCT02969018
  • 12% vs 8.7% 30 mg QD Followed by 10 mg QD · wk 16 · n 25 · Phase 2 · secondary NCT02969018
  • 16.7% vs 8.7% 30 mg QD Followed by 100 mg QW · wk 16 · n 30 · Phase 2 · secondary NCT02969018
  • 51.7% vs 8.7% 30 mg QD · wk 6 · n 29 · Phase 2 · secondary NCT02969018
  • 28% vs 8.7% 30 mg QD Followed by 10 mg QD · wk 6 · n 25 · Phase 2 · secondary NCT02969018
  • 26.7% vs 8.7% 30 mg QD Followed by 100 mg QW · wk 6 · n 30 · Phase 2 · secondary NCT02969018
  • 27.6% vs 0% 30 mg QD · wk 4 · n 29 · Phase 2 · secondary NCT02969018
  • 24% vs 0% 30 mg QD Followed by 10 mg QD · wk 4 · n 25 · Phase 2 · secondary NCT02969018
  • 36.7% vs 0% 30 mg QD Followed by 100 mg QW · wk 4 · n 30 · Phase 2 · secondary NCT02969018
  • 3.4% vs 0% 30 mg QD · wk 2 · n 29 · Phase 2 · secondary NCT02969018
  • 8% vs 0% 30 mg QD Followed by 10 mg QD · wk 2 · n 25 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 30 mg QD Followed by 100 mg QW · wk 2 · n 30 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 30 mg QD · wk 1 · n 29 · Phase 2 · secondary NCT02969018
  • 4% vs 0% 30 mg QD Followed by 10 mg QD · wk 1 · n 25 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 30 mg QD Followed by 100 mg QW · wk 1 · n 30 · Phase 2 · secondary NCT02969018
  • 10.3% vs 20.6% 0.1% QD · wk 12 · n 36 · Phase 2 · secondary NCT03850483
  • 7.7% vs 20.6% 0.3% QD · wk 12 · n 34 · Phase 2 · secondary NCT03850483
  • 20.7% vs 20.6% 1.0% QD · wk 12 · n 35 · Phase 2 · secondary NCT03850483
  • 17.9% vs 20.6% 3.0% QD · wk 12 · n 35 · Phase 2 · secondary NCT03850483
  • 12.5% vs 20.6% 0.3% BID · wk 12 · n 35 · Phase 2 · secondary NCT03850483
  • 24.1% vs 20.6% 1.0% BID · wk 12 · n 34 · Phase 2 · secondary NCT03850483
  • 17.9% vs 20.6% 3.0% BID · wk 12 · n 37 · Phase 2 · secondary NCT03850483
  • 3.3% vs 18.2% 0.1% QD · wk 10 · n 36 · Phase 2 · secondary NCT03850483
  • 8% vs 18.2% 0.3% QD · wk 10 · n 34 · Phase 2 · secondary NCT03850483
  • 17.2% vs 18.2% 1.0% QD · wk 10 · n 35 · Phase 2 · secondary NCT03850483
  • 14.3% vs 18.2% 3.0% QD · wk 10 · n 35 · Phase 2 · secondary NCT03850483
  • 20.8% vs 18.2% 0.3% BID · wk 10 · n 35 · Phase 2 · secondary NCT03850483
  • 10.7% vs 18.2% 1.0% BID · wk 10 · n 34 · Phase 2 · secondary NCT03850483
  • 15.4% vs 18.2% 3.0% BID · wk 10 · n 37 · Phase 2 · secondary NCT03850483
  • 7.7% vs 10.3% 0.1% QD · wk 14 · n 36 · Phase 2 · secondary NCT03850483
  • 8.7% vs 10.3% 0.3% QD · wk 14 · n 34 · Phase 2 · secondary NCT03850483
  • 21.4% vs 10.3% 1.0% QD · wk 14 · n 35 · Phase 2 · secondary NCT03850483
  • 14.3% vs 10.3% 3.0% QD · wk 14 · n 35 · Phase 2 · secondary NCT03850483
  • 13% vs 10.3% 0.3% BID · wk 14 · n 35 · Phase 2 · secondary NCT03850483
  • 20% vs 10.3% 1.0% BID · wk 14 · n 34 · Phase 2 · secondary NCT03850483
  • 14.8% vs 10.3% 3.0% BID · wk 14 · n 37 · Phase 2 · secondary NCT03850483
  • 6.7% vs 13.9% 0.1% QD · wk 8 · n 36 · Phase 2 · secondary NCT03850483
  • 7.4% vs 13.9% 0.3% QD · wk 8 · n 34 · Phase 2 · secondary NCT03850483
  • 6.5% vs 13.9% 1.0% QD · wk 8 · n 35 · Phase 2 · secondary NCT03850483
  • 14.3% vs 13.9% 3.0% QD · wk 8 · n 35 · Phase 2 · secondary NCT03850483
  • 16% vs 13.9% 0.3% BID · wk 8 · n 35 · Phase 2 · secondary NCT03850483
  • 13.8% vs 13.9% 1.0% BID · wk 8 · n 34 · Phase 2 · secondary NCT03850483
  • 14.3% vs 13.9% 3.0% BID · wk 8 · n 37 · Phase 2 · secondary NCT03850483
  • 11.1% vs 16.1% 0.1% QD · wk 16 · n 36 · Phase 2 · secondary NCT03850483
  • 17.4% vs 16.1% 0.3% QD · wk 16 · n 34 · Phase 2 · secondary NCT03850483
  • 25% vs 16.1% 1.0% QD · wk 16 · n 35 · Phase 2 · secondary NCT03850483
  • 15.4% vs 16.1% 3.0% QD · wk 16 · n 35 · Phase 2 · secondary NCT03850483
  • 13% vs 16.1% 0.3% BID · wk 16 · n 35 · Phase 2 · secondary NCT03850483
  • 12.5% vs 16.1% 1.0% BID · wk 16 · n 34 · Phase 2 · secondary NCT03850483
  • 15.4% vs 16.1% 3.0% BID · wk 16 · n 37 · Phase 2 · secondary NCT03850483
  • 0% vs 13.9% 0.1% QD · wk 6 · n 36 · Phase 2 · secondary NCT03850483
  • 7.4% vs 13.9% 0.3% QD · wk 6 · n 34 · Phase 2 · secondary NCT03850483
  • 6.5% vs 13.9% 1.0% QD · wk 6 · n 35 · Phase 2 · secondary NCT03850483
  • 10.3% vs 13.9% 3.0% QD · wk 6 · n 35 · Phase 2 · secondary NCT03850483
  • 10.7% vs 13.9% 0.3% BID · wk 6 · n 35 · Phase 2 · secondary NCT03850483
  • 10.7% vs 13.9% 1.0% BID · wk 6 · n 34 · Phase 2 · secondary NCT03850483
  • 10.3% vs 13.9% 3.0% BID · wk 6 · n 37 · Phase 2 · secondary NCT03850483
  • 0% vs 8.9% 0.1% QD · wk 4 · n 36 · Phase 2 · secondary NCT03850483
  • 3.6% vs 8.9% 0.3% QD · wk 4 · n 34 · Phase 2 · secondary NCT03850483
  • 0% vs 8.9% 1.0% QD · wk 4 · n 35 · Phase 2 · secondary NCT03850483
  • 0% vs 8.9% 3.0% QD · wk 4 · n 35 · Phase 2 · secondary NCT03850483
  • 6.7% vs 8.9% 0.3% BID · wk 4 · n 35 · Phase 2 · secondary NCT03850483
  • 3% vs 8.9% 1.0% BID · wk 4 · n 34 · Phase 2 · secondary NCT03850483
  • 12.1% vs 8.9% 3.0% BID · wk 4 · n 37 · Phase 2 · secondary NCT03850483
  • 0% vs 2.2% 0.1% QD · wk 2 · n 36 · Phase 2 · secondary NCT03850483
  • 0% vs 2.2% 0.3% QD · wk 2 · n 34 · Phase 2 · secondary NCT03850483
  • 2.9% vs 2.2% 1.0% QD · wk 2 · n 35 · Phase 2 · secondary NCT03850483
  • 0% vs 2.2% 3.0% QD · wk 2 · n 35 · Phase 2 · secondary NCT03850483
  • 0% vs 2.2% 0.3% BID · wk 2 · n 35 · Phase 2 · secondary NCT03850483
  • 6.3% vs 2.2% 1.0% BID · wk 2 · n 34 · Phase 2 · secondary NCT03850483
  • 5.7% vs 2.2% 3.0% BID · wk 2 · n 37 · Phase 2 · secondary NCT03850483
  • 3% vs 0% 0.1% QD · wk 1 · n 36 · Phase 2 · secondary NCT03850483
  • 0% vs 0% 0.3% QD · wk 1 · n 34 · Phase 2 · secondary NCT03850483
  • 0% vs 0% 1.0% QD · wk 1 · n 35 · Phase 2 · secondary NCT03850483
  • 0% vs 0% 3.0% QD · wk 1 · n 35 · Phase 2 · secondary NCT03850483
  • 0% vs 0% 0.3% BID · wk 1 · n 35 · Phase 2 · secondary NCT03850483
  • 2.9% vs 0% 1.0% BID · wk 1 · n 34 · Phase 2 · secondary NCT03850483
  • 2.7% vs 0% 3.0% BID · wk 1 · n 37 · Phase 2 · secondary NCT03850483
35.5% vs 21.4%+14.1 vs placebowk 12 · n 31NCT05772520
5 other results
  • 44.8% vs 21.4% wk 12 · n 29 · Phase 2 · primary NCT05772520
  • 50% vs 21.4% wk 12 · n 8 · Phase 2 · primary NCT05772520
  • 50% vs 25% wk 12 · n 18 · Phase 2 · primary NCT05772520
  • 61.1% vs 25% wk 12 · n 18 · Phase 2 · primary NCT05772520
  • 50% vs 25% wk 12 · n 8 · Phase 2 · primary NCT05772520
PASI 9020% vs 4.3%+15.7 vs placebo60 mg Once Daily (QD) Followed by 30 mg QD · wk 16 · n 25NCT02969018
62 other results
  • 3.4% vs 4.3% 60 mg QD Followed by 10 mg QD · wk 16 · n 29 · Phase 2 · secondary NCT02969018
  • 15.4% vs 4.3% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 16 · n 26 · Phase 2 · secondary NCT02969018
  • 4% vs 4.3% 60 mg QD Followed by Placebo · wk 16 · n 25 · Phase 2 · secondary NCT02969018
  • 28% vs 4.3% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 14 · n 25 · Phase 2 · secondary NCT02969018
  • 13.8% vs 4.3% 60 mg QD Followed by 10 mg QD · wk 14 · n 29 · Phase 2 · secondary NCT02969018
  • 11.5% vs 4.3% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 14 · n 26 · Phase 2 · secondary NCT02969018
  • 8% vs 4.3% 60 mg QD Followed by Placebo · wk 14 · n 25 · Phase 2 · secondary NCT02969018
  • 36% vs 4.3% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 12 · n 25 · Phase 2 · secondary NCT02969018
  • 13.8% vs 4.3% 60 mg QD Followed by 10 mg QD · wk 12 · n 29 · Phase 2 · secondary NCT02969018
  • 26.9% vs 4.3% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 12 · n 26 · Phase 2 · secondary NCT02969018
  • 8% vs 4.3% 60 mg QD Followed by Placebo · wk 12 · n 25 · Phase 2 · secondary NCT02969018
  • 28% vs 4.3% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 10 · n 25 · Phase 2 · secondary NCT02969018
  • 17.2% vs 4.3% 60 mg QD Followed by 10 mg QD · wk 10 · n 29 · Phase 2 · secondary NCT02969018
  • 26.9% vs 4.3% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 10 · n 26 · Phase 2 · secondary NCT02969018
  • 8% vs 4.3% 60 mg QD Followed by Placebo · wk 10 · n 25 · Phase 2 · secondary NCT02969018
  • 24% vs 0% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 8 · n 25 · Phase 2 · secondary NCT02969018
  • 17.2% vs 0% 60 mg QD Followed by 10 mg QD · wk 8 · n 29 · Phase 2 · secondary NCT02969018
  • 30.8% vs 0% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 8 · n 26 · Phase 2 · secondary NCT02969018
  • 8% vs 0% 60 mg QD Followed by Placebo · wk 8 · n 25 · Phase 2 · secondary NCT02969018
  • 16% vs 0% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 6 · n 25 · Phase 2 · secondary NCT02969018
  • 20.7% vs 0% 60 mg QD Followed by 10 mg QD · wk 6 · n 29 · Phase 2 · secondary NCT02969018
  • 26.9% vs 0% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 6 · n 26 · Phase 2 · secondary NCT02969018
  • 12% vs 0% 60 mg QD Followed by Placebo · wk 6 · n 25 · Phase 2 · secondary NCT02969018
  • 12% vs 0% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 4 · n 25 · Phase 2 · secondary NCT02969018
  • 20.7% vs 0% 60 mg QD Followed by 10 mg QD · wk 4 · n 29 · Phase 2 · secondary NCT02969018
  • 42.3% vs 0% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 4 · n 26 · Phase 2 · secondary NCT02969018
  • 16% vs 0% 60 mg QD Followed by Placebo · wk 4 · n 25 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 2 · n 25 · Phase 2 · secondary NCT02969018
  • 3.4% vs 0% 60 mg QD Followed by 10 mg QD · wk 2 · n 29 · Phase 2 · secondary NCT02969018
  • 7.7% vs 0% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 2 · n 26 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 60 mg QD Followed by Placebo · wk 2 · n 25 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 1 · n 25 · Phase 2 · secondary NCT02969018
  • 3.4% vs 0% 60 mg QD Followed by 10 mg QD · wk 1 · n 29 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 1 · n 26 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 60 mg QD Followed by Placebo · wk 1 · n 25 · Phase 2 · secondary NCT02969018
  • 27.6% vs 4.3% 30 mg QD · wk 16 · n 29 · Phase 2 · secondary NCT02969018
  • 8% vs 4.3% 30 mg QD Followed by 10 mg QD · wk 16 · n 25 · Phase 2 · secondary NCT02969018
  • 10% vs 4.3% 30 mg QD Followed by 100 mg QW · wk 16 · n 30 · Phase 2 · secondary NCT02969018
  • 37.9% vs 4.3% 30 mg QD · wk 14 · n 29 · Phase 2 · secondary NCT02969018
  • 4% vs 4.3% 30 mg QD Followed by 10 mg QD · wk 14 · n 25 · Phase 2 · secondary NCT02969018
  • 13.3% vs 4.3% 30 mg QD Followed by 100 mg QW · wk 14 · n 30 · Phase 2 · secondary NCT02969018
  • 51.7% vs 4.3% 30 mg QD · wk 12 · n 29 · Phase 2 · secondary NCT02969018
  • 8% vs 4.3% 30 mg QD Followed by 10 mg QD · wk 12 · n 25 · Phase 2 · secondary NCT02969018
  • 10% vs 4.3% 30 mg QD Followed by 100 mg QW · wk 12 · n 30 · Phase 2 · secondary NCT02969018
  • 34.5% vs 4.3% 30 mg QD · wk 10 · n 29 · Phase 2 · secondary NCT02969018
  • 8% vs 4.3% 30 mg QD Followed by 10 mg QD · wk 10 · n 25 · Phase 2 · secondary NCT02969018
  • 13.3% vs 4.3% 30 mg QD Followed by 100 mg QW · wk 10 · n 30 · Phase 2 · secondary NCT02969018
  • 34.5% vs 0% 30 mg QD · wk 8 · n 29 · Phase 2 · secondary NCT02969018
  • 4% vs 0% 30 mg QD Followed by 10 mg QD · wk 8 · n 25 · Phase 2 · secondary NCT02969018
  • 16.7% vs 0% 30 mg QD Followed by 100 mg QW · wk 8 · n 30 · Phase 2 · secondary NCT02969018
  • 24.1% vs 0% 30 mg QD · wk 6 · n 29 · Phase 2 · secondary NCT02969018
  • 8% vs 0% 30 mg QD Followed by 10 mg QD · wk 6 · n 25 · Phase 2 · secondary NCT02969018
  • 20% vs 0% 30 mg QD Followed by 100 mg QW · wk 6 · n 30 · Phase 2 · secondary NCT02969018
  • 6.9% vs 0% 30 mg QD · wk 4 · n 29 · Phase 2 · secondary NCT02969018
  • 8% vs 0% 30 mg QD Followed by 10 mg QD · wk 4 · n 25 · Phase 2 · secondary NCT02969018
  • 3.3% vs 0% 30 mg QD Followed by 100 mg QW · wk 4 · n 30 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 30 mg QD · wk 2 · n 29 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 30 mg QD Followed by 10 mg QD · wk 2 · n 25 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 30 mg QD Followed by 100 mg QW · wk 2 · n 30 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 30 mg QD · wk 1 · n 29 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 30 mg QD Followed by 10 mg QD · wk 1 · n 25 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 30 mg QD Followed by 100 mg QW · wk 1 · n 30 · Phase 2 · secondary NCT02969018
—Not reported
PASI 100—Not reported—Not reported
sPGA 0/111.4% vs 8.2%+3.2 vs placebo0.1% QD · wk 16 · n 37NCT03850483
62 other results
  • 8.6% vs 8.2% 0.3% QD · wk 16 · n 37 · Phase 2 · secondary NCT03850483
  • 14.3% vs 8.2% 1.0% QD · wk 16 · n 36 · Phase 2 · secondary NCT03850483
  • 16.2% vs 8.2% 3.0% QD · wk 16 · n 37 · Phase 2 · secondary NCT03850483
  • 14.7% vs 8.2% 0.3% BID · wk 16 · n 36 · Phase 2 · secondary NCT03850483
  • 11.8% vs 8.2% 1.0% BID · wk 16 · n 35 · Phase 2 · secondary NCT03850483
  • 16.2% vs 8.2% 3.0% BID · wk 16 · n 38 · Phase 2 · secondary NCT03850483
  • 13.5% vs 6.3% 0.1% QD · wk 14 · n 37 · Phase 2 · secondary NCT03850483
  • 5.6% vs 6.3% 0.3% QD · wk 14 · n 37 · Phase 2 · secondary NCT03850483
  • 8.6% vs 6.3% 1.0% QD · wk 14 · n 36 · Phase 2 · secondary NCT03850483
  • 13.5% vs 6.3% 3.0% QD · wk 14 · n 37 · Phase 2 · secondary NCT03850483
  • 8.8% vs 6.3% 0.3% BID · wk 14 · n 36 · Phase 2 · secondary NCT03850483
  • 11.8% vs 6.3% 1.0% BID · wk 14 · n 35 · Phase 2 · secondary NCT03850483
  • 8.1% vs 6.3% 3.0% BID · wk 14 · n 38 · Phase 2 · secondary NCT03850483
  • 10.3% vs 14.7% 0.1% QD · wk 12 · n 29 · Phase 2 · secondary NCT03850483
  • 15.4% vs 14.7% 0.3% QD · wk 12 · n 26 · Phase 2 · secondary NCT03850483
  • 10.3% vs 14.7% 1.0% QD · wk 12 · n 29 · Phase 2 · secondary NCT03850483
  • 21.4% vs 14.7% 3.0% QD · wk 12 · n 28 · Phase 2 · secondary NCT03850483
  • 20.8% vs 14.7% 0.3% BID · wk 12 · n 24 · Phase 2 · secondary NCT03850483
  • 27.6% vs 14.7% 1.0% BID · wk 12 · n 29 · Phase 2 · secondary NCT03850483
  • 17.9% vs 14.7% 3.0% BID · wk 12 · n 28 · Phase 2 · secondary NCT03850483
  • 5.4% vs 16.3% 0.1% QD · wk 10 · n 37 · Phase 2 · secondary NCT03850483
  • 8.1% vs 16.3% 0.3% QD · wk 10 · n 37 · Phase 2 · secondary NCT03850483
  • 8.3% vs 16.3% 1.0% QD · wk 10 · n 36 · Phase 2 · secondary NCT03850483
  • 16.2% vs 16.3% 3.0% QD · wk 10 · n 37 · Phase 2 · secondary NCT03850483
  • 16.7% vs 16.3% 0.3% BID · wk 10 · n 36 · Phase 2 · secondary NCT03850483
  • 8.6% vs 16.3% 1.0% BID · wk 10 · n 35 · Phase 2 · secondary NCT03850483
  • 13.2% vs 16.3% 3.0% BID · wk 10 · n 38 · Phase 2 · secondary NCT03850483
  • 5.4% vs 6.1% 0.1% QD · wk 8 · n 37 · Phase 2 · secondary NCT03850483
  • 5.4% vs 6.1% 0.3% QD · wk 8 · n 37 · Phase 2 · secondary NCT03850483
  • 2.8% vs 6.1% 1.0% QD · wk 8 · n 36 · Phase 2 · secondary NCT03850483
  • 10.8% vs 6.1% 3.0% QD · wk 8 · n 37 · Phase 2 · secondary NCT03850483
  • 13.9% vs 6.1% 0.3% BID · wk 8 · n 36 · Phase 2 · secondary NCT03850483
  • 5.7% vs 6.1% 1.0% BID · wk 8 · n 35 · Phase 2 · secondary NCT03850483
  • 18.4% vs 6.1% 3.0% BID · wk 8 · n 38 · Phase 2 · secondary NCT03850483
  • 5.4% vs 8.2% 0.1% QD · wk 6 · n 37 · Phase 2 · secondary NCT03850483
  • 2.7% vs 8.2% 0.3% QD · wk 6 · n 37 · Phase 2 · secondary NCT03850483
  • 8.3% vs 8.2% 1.0% QD · wk 6 · n 36 · Phase 2 · secondary NCT03850483
  • 13.5% vs 8.2% 3.0% QD · wk 6 · n 37 · Phase 2 · secondary NCT03850483
  • 8.3% vs 8.2% 0.3% BID · wk 6 · n 36 · Phase 2 · secondary NCT03850483
  • 5.7% vs 8.2% 1.0% BID · wk 6 · n 35 · Phase 2 · secondary NCT03850483
  • 13.2% vs 8.2% 3.0% BID · wk 6 · n 38 · Phase 2 · secondary NCT03850483
  • 5.4% vs 8.2% 0.1% QD · wk 4 · n 37 · Phase 2 · secondary NCT03850483
  • 0% vs 8.2% 0.3% QD · wk 4 · n 37 · Phase 2 · secondary NCT03850483
  • 5.6% vs 8.2% 1.0% QD · wk 4 · n 36 · Phase 2 · secondary NCT03850483
  • 5.4% vs 8.2% 3.0% QD · wk 4 · n 37 · Phase 2 · secondary NCT03850483
  • 8.3% vs 8.2% 0.3% BID · wk 4 · n 36 · Phase 2 · secondary NCT03850483
  • 11.4% vs 8.2% 1.0% BID · wk 4 · n 35 · Phase 2 · secondary NCT03850483
  • 21.1% vs 8.2% 3.0% BID · wk 4 · n 38 · Phase 2 · secondary NCT03850483
  • 0% vs 2% 0.1% QD · wk 2 · n 37 · Phase 2 · secondary NCT03850483
  • 0% vs 2% 0.3% QD · wk 2 · n 37 · Phase 2 · secondary NCT03850483
  • 2.8% vs 2% 1.0% QD · wk 2 · n 36 · Phase 2 · secondary NCT03850483
  • 2.7% vs 2% 3.0% QD · wk 2 · n 37 · Phase 2 · secondary NCT03850483
  • 0% vs 2% 0.3% BID · wk 2 · n 36 · Phase 2 · secondary NCT03850483
  • 5.7% vs 2% 1.0% BID · wk 2 · n 35 · Phase 2 · secondary NCT03850483
  • 10.5% vs 2% 3.0% BID · wk 2 · n 38 · Phase 2 · secondary NCT03850483
  • 2.7% vs 0% 0.1% QD · wk 1 · n 37 · Phase 2 · secondary NCT03850483
  • 2.7% vs 0% 0.3% QD · wk 1 · n 37 · Phase 2 · secondary NCT03850483
  • 0% vs 0% 1.0% QD · wk 1 · n 36 · Phase 2 · secondary NCT03850483
  • 0% vs 0% 3.0% QD · wk 1 · n 37 · Phase 2 · secondary NCT03850483
  • 0% vs 0% 0.3% BID · wk 1 · n 36 · Phase 2 · secondary NCT03850483
  • 5.7% vs 0% 1.0% BID · wk 1 · n 35 · Phase 2 · secondary NCT03850483
  • 5.3% vs 0% 3.0% BID · wk 1 · n 38 · Phase 2 · secondary NCT03850483
—Not reported
DLQI, change—Not reported—Not reported

PASI 75

brepocitinib
60% vs 13%+47 vs placebo60 mg Once Daily (QD) Followed by 30 mg QD · wk 12 · n 25NCT02969018
125 other results
  • 24.1% vs 13% 60 mg QD Followed by 10 mg QD · wk 12 · n 29 · Phase 2 · secondary NCT02969018
  • 57.7% vs 13% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 12 · n 26 · Phase 2 · secondary NCT02969018
  • 24% vs 13% 60 mg QD Followed by Placebo · wk 12 · n 25 · Phase 2 · secondary NCT02969018
  • 48% vs 13% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 10 · n 25 · Phase 2 · secondary NCT02969018
  • 24.1% vs 13% 60 mg QD Followed by 10 mg QD · wk 10 · n 29 · Phase 2 · secondary NCT02969018
  • 61.5% vs 13% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 10 · n 26 · Phase 2 · secondary NCT02969018
  • 32% vs 13% 60 mg QD Followed by Placebo · wk 10 · n 25 · Phase 2 · secondary NCT02969018
  • 48% vs 8.7% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 14 · n 25 · Phase 2 · secondary NCT02969018
  • 17.2% vs 8.7% 60 mg QD Followed by 10 mg QD · wk 14 · n 29 · Phase 2 · secondary NCT02969018
  • 34.6% vs 8.7% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 14 · n 26 · Phase 2 · secondary NCT02969018
  • 16% vs 8.7% 60 mg QD Followed by Placebo · wk 14 · n 25 · Phase 2 · secondary NCT02969018
  • 60% vs 8.7% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 8 · n 25 · Phase 2 · secondary NCT02969018
  • 37.9% vs 8.7% 60 mg QD Followed by 10 mg QD · wk 8 · n 29 · Phase 2 · secondary NCT02969018
  • 65.4% vs 8.7% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 8 · n 26 · Phase 2 · secondary NCT02969018
  • 32% vs 8.7% 60 mg QD Followed by Placebo · wk 8 · n 25 · Phase 2 · secondary NCT02969018
  • 36% vs 8.7% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 16 · n 25 · Phase 2 · secondary NCT02969018
  • 10.3% vs 8.7% 60 mg QD Followed by 10 mg QD · wk 16 · n 29 · Phase 2 · secondary NCT02969018
  • 30.8% vs 8.7% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 16 · n 26 · Phase 2 · secondary NCT02969018
  • 20% vs 8.7% 60 mg QD Followed by Placebo · wk 16 · n 25 · Phase 2 · secondary NCT02969018
  • 44% vs 8.7% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 6 · n 25 · Phase 2 · secondary NCT02969018
  • 41.4% vs 8.7% 60 mg QD Followed by 10 mg QD · wk 6 · n 29 · Phase 2 · secondary NCT02969018
  • 65.4% vs 8.7% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 6 · n 26 · Phase 2 · secondary NCT02969018
  • 36% vs 8.7% 60 mg QD Followed by Placebo · wk 6 · n 25 · Phase 2 · secondary NCT02969018
  • 24% vs 0% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 4 · n 25 · Phase 2 · secondary NCT02969018
  • 41.4% vs 0% 60 mg QD Followed by 10 mg QD · wk 4 · n 29 · Phase 2 · secondary NCT02969018
  • 61.5% vs 0% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 4 · n 26 · Phase 2 · secondary NCT02969018
  • 36% vs 0% 60 mg QD Followed by Placebo · wk 4 · n 25 · Phase 2 · secondary NCT02969018
  • 8% vs 0% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 2 · n 25 · Phase 2 · secondary NCT02969018
  • 13.8% vs 0% 60 mg QD Followed by 10 mg QD · wk 2 · n 29 · Phase 2 · secondary NCT02969018
  • 26.9% vs 0% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 2 · n 26 · Phase 2 · secondary NCT02969018
  • 12% vs 0% 60 mg QD Followed by Placebo · wk 2 · n 25 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 1 · n 25 · Phase 2 · secondary NCT02969018
  • 6.9% vs 0% 60 mg QD Followed by 10 mg QD · wk 1 · n 29 · Phase 2 · secondary NCT02969018
  • 7.7% vs 0% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 1 · n 26 · Phase 2 · secondary NCT02969018
  • 4% vs 0% 60 mg QD Followed by Placebo · wk 1 · n 25 · Phase 2 · secondary NCT02969018
  • 86.2% vs 13% 30 mg QD · wk 12 · n 29 · Phase 2 · secondary NCT02969018
  • 24% vs 13% 30 mg QD Followed by 10 mg QD · wk 12 · n 25 · Phase 2 · secondary NCT02969018
  • 36.7% vs 13% 30 mg QD Followed by 100 mg QW · wk 12 · n 30 · Phase 2 · secondary NCT02969018
  • 72.4% vs 13% 30 mg QD · wk 10 · n 29 · Phase 2 · secondary NCT02969018
  • 28% vs 13% 30 mg QD Followed by 10 mg QD · wk 10 · n 25 · Phase 2 · secondary NCT02969018
  • 46.7% vs 13% 30 mg QD Followed by 100 mg QW · wk 10 · n 30 · Phase 2 · secondary NCT02969018
  • 75.9% vs 8.7% 30 mg QD · wk 14 · n 29 · Phase 2 · secondary NCT02969018
  • 16% vs 8.7% 30 mg QD Followed by 10 mg QD · wk 14 · n 25 · Phase 2 · secondary NCT02969018
  • 16.7% vs 8.7% 30 mg QD Followed by 100 mg QW · wk 14 · n 30 · Phase 2 · secondary NCT02969018
  • 65.5% vs 8.7% 30 mg QD · wk 8 · n 29 · Phase 2 · secondary NCT02969018
  • 20% vs 8.7% 30 mg QD Followed by 10 mg QD · wk 8 · n 25 · Phase 2 · secondary NCT02969018
  • 40% vs 8.7% 30 mg QD Followed by 100 mg QW · wk 8 · n 30 · Phase 2 · secondary NCT02969018
  • 58.6% vs 8.7% 30 mg QD · wk 16 · n 29 · Phase 2 · secondary NCT02969018
  • 12% vs 8.7% 30 mg QD Followed by 10 mg QD · wk 16 · n 25 · Phase 2 · secondary NCT02969018
  • 16.7% vs 8.7% 30 mg QD Followed by 100 mg QW · wk 16 · n 30 · Phase 2 · secondary NCT02969018
  • 51.7% vs 8.7% 30 mg QD · wk 6 · n 29 · Phase 2 · secondary NCT02969018
  • 28% vs 8.7% 30 mg QD Followed by 10 mg QD · wk 6 · n 25 · Phase 2 · secondary NCT02969018
  • 26.7% vs 8.7% 30 mg QD Followed by 100 mg QW · wk 6 · n 30 · Phase 2 · secondary NCT02969018
  • 27.6% vs 0% 30 mg QD · wk 4 · n 29 · Phase 2 · secondary NCT02969018
  • 24% vs 0% 30 mg QD Followed by 10 mg QD · wk 4 · n 25 · Phase 2 · secondary NCT02969018
  • 36.7% vs 0% 30 mg QD Followed by 100 mg QW · wk 4 · n 30 · Phase 2 · secondary NCT02969018
  • 3.4% vs 0% 30 mg QD · wk 2 · n 29 · Phase 2 · secondary NCT02969018
  • 8% vs 0% 30 mg QD Followed by 10 mg QD · wk 2 · n 25 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 30 mg QD Followed by 100 mg QW · wk 2 · n 30 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 30 mg QD · wk 1 · n 29 · Phase 2 · secondary NCT02969018
  • 4% vs 0% 30 mg QD Followed by 10 mg QD · wk 1 · n 25 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 30 mg QD Followed by 100 mg QW · wk 1 · n 30 · Phase 2 · secondary NCT02969018
  • 10.3% vs 20.6% 0.1% QD · wk 12 · n 36 · Phase 2 · secondary NCT03850483
  • 7.7% vs 20.6% 0.3% QD · wk 12 · n 34 · Phase 2 · secondary NCT03850483
  • 20.7% vs 20.6% 1.0% QD · wk 12 · n 35 · Phase 2 · secondary NCT03850483
  • 17.9% vs 20.6% 3.0% QD · wk 12 · n 35 · Phase 2 · secondary NCT03850483
  • 12.5% vs 20.6% 0.3% BID · wk 12 · n 35 · Phase 2 · secondary NCT03850483
  • 24.1% vs 20.6% 1.0% BID · wk 12 · n 34 · Phase 2 · secondary NCT03850483
  • 17.9% vs 20.6% 3.0% BID · wk 12 · n 37 · Phase 2 · secondary NCT03850483
  • 3.3% vs 18.2% 0.1% QD · wk 10 · n 36 · Phase 2 · secondary NCT03850483
  • 8% vs 18.2% 0.3% QD · wk 10 · n 34 · Phase 2 · secondary NCT03850483
  • 17.2% vs 18.2% 1.0% QD · wk 10 · n 35 · Phase 2 · secondary NCT03850483
  • 14.3% vs 18.2% 3.0% QD · wk 10 · n 35 · Phase 2 · secondary NCT03850483
  • 20.8% vs 18.2% 0.3% BID · wk 10 · n 35 · Phase 2 · secondary NCT03850483
  • 10.7% vs 18.2% 1.0% BID · wk 10 · n 34 · Phase 2 · secondary NCT03850483
  • 15.4% vs 18.2% 3.0% BID · wk 10 · n 37 · Phase 2 · secondary NCT03850483
  • 7.7% vs 10.3% 0.1% QD · wk 14 · n 36 · Phase 2 · secondary NCT03850483
  • 8.7% vs 10.3% 0.3% QD · wk 14 · n 34 · Phase 2 · secondary NCT03850483
  • 21.4% vs 10.3% 1.0% QD · wk 14 · n 35 · Phase 2 · secondary NCT03850483
  • 14.3% vs 10.3% 3.0% QD · wk 14 · n 35 · Phase 2 · secondary NCT03850483
  • 13% vs 10.3% 0.3% BID · wk 14 · n 35 · Phase 2 · secondary NCT03850483
  • 20% vs 10.3% 1.0% BID · wk 14 · n 34 · Phase 2 · secondary NCT03850483
  • 14.8% vs 10.3% 3.0% BID · wk 14 · n 37 · Phase 2 · secondary NCT03850483
  • 6.7% vs 13.9% 0.1% QD · wk 8 · n 36 · Phase 2 · secondary NCT03850483
  • 7.4% vs 13.9% 0.3% QD · wk 8 · n 34 · Phase 2 · secondary NCT03850483
  • 6.5% vs 13.9% 1.0% QD · wk 8 · n 35 · Phase 2 · secondary NCT03850483
  • 14.3% vs 13.9% 3.0% QD · wk 8 · n 35 · Phase 2 · secondary NCT03850483
  • 16% vs 13.9% 0.3% BID · wk 8 · n 35 · Phase 2 · secondary NCT03850483
  • 13.8% vs 13.9% 1.0% BID · wk 8 · n 34 · Phase 2 · secondary NCT03850483
  • 14.3% vs 13.9% 3.0% BID · wk 8 · n 37 · Phase 2 · secondary NCT03850483
  • 11.1% vs 16.1% 0.1% QD · wk 16 · n 36 · Phase 2 · secondary NCT03850483
  • 17.4% vs 16.1% 0.3% QD · wk 16 · n 34 · Phase 2 · secondary NCT03850483
  • 25% vs 16.1% 1.0% QD · wk 16 · n 35 · Phase 2 · secondary NCT03850483
  • 15.4% vs 16.1% 3.0% QD · wk 16 · n 35 · Phase 2 · secondary NCT03850483
  • 13% vs 16.1% 0.3% BID · wk 16 · n 35 · Phase 2 · secondary NCT03850483
  • 12.5% vs 16.1% 1.0% BID · wk 16 · n 34 · Phase 2 · secondary NCT03850483
  • 15.4% vs 16.1% 3.0% BID · wk 16 · n 37 · Phase 2 · secondary NCT03850483
  • 0% vs 13.9% 0.1% QD · wk 6 · n 36 · Phase 2 · secondary NCT03850483
  • 7.4% vs 13.9% 0.3% QD · wk 6 · n 34 · Phase 2 · secondary NCT03850483
  • 6.5% vs 13.9% 1.0% QD · wk 6 · n 35 · Phase 2 · secondary NCT03850483
  • 10.3% vs 13.9% 3.0% QD · wk 6 · n 35 · Phase 2 · secondary NCT03850483
  • 10.7% vs 13.9% 0.3% BID · wk 6 · n 35 · Phase 2 · secondary NCT03850483
  • 10.7% vs 13.9% 1.0% BID · wk 6 · n 34 · Phase 2 · secondary NCT03850483
  • 10.3% vs 13.9% 3.0% BID · wk 6 · n 37 · Phase 2 · secondary NCT03850483
  • 0% vs 8.9% 0.1% QD · wk 4 · n 36 · Phase 2 · secondary NCT03850483
  • 3.6% vs 8.9% 0.3% QD · wk 4 · n 34 · Phase 2 · secondary NCT03850483
  • 0% vs 8.9% 1.0% QD · wk 4 · n 35 · Phase 2 · secondary NCT03850483
  • 0% vs 8.9% 3.0% QD · wk 4 · n 35 · Phase 2 · secondary NCT03850483
  • 6.7% vs 8.9% 0.3% BID · wk 4 · n 35 · Phase 2 · secondary NCT03850483
  • 3% vs 8.9% 1.0% BID · wk 4 · n 34 · Phase 2 · secondary NCT03850483
  • 12.1% vs 8.9% 3.0% BID · wk 4 · n 37 · Phase 2 · secondary NCT03850483
  • 0% vs 2.2% 0.1% QD · wk 2 · n 36 · Phase 2 · secondary NCT03850483
  • 0% vs 2.2% 0.3% QD · wk 2 · n 34 · Phase 2 · secondary NCT03850483
  • 2.9% vs 2.2% 1.0% QD · wk 2 · n 35 · Phase 2 · secondary NCT03850483
  • 0% vs 2.2% 3.0% QD · wk 2 · n 35 · Phase 2 · secondary NCT03850483
  • 0% vs 2.2% 0.3% BID · wk 2 · n 35 · Phase 2 · secondary NCT03850483
  • 6.3% vs 2.2% 1.0% BID · wk 2 · n 34 · Phase 2 · secondary NCT03850483
  • 5.7% vs 2.2% 3.0% BID · wk 2 · n 37 · Phase 2 · secondary NCT03850483
  • 3% vs 0% 0.1% QD · wk 1 · n 36 · Phase 2 · secondary NCT03850483
  • 0% vs 0% 0.3% QD · wk 1 · n 34 · Phase 2 · secondary NCT03850483
  • 0% vs 0% 1.0% QD · wk 1 · n 35 · Phase 2 · secondary NCT03850483
  • 0% vs 0% 3.0% QD · wk 1 · n 35 · Phase 2 · secondary NCT03850483
  • 0% vs 0% 0.3% BID · wk 1 · n 35 · Phase 2 · secondary NCT03850483
  • 2.9% vs 0% 1.0% BID · wk 1 · n 34 · Phase 2 · secondary NCT03850483
  • 2.7% vs 0% 3.0% BID · wk 1 · n 37 · Phase 2 · secondary NCT03850483
Girocitinib
35.5% vs 21.4%+14.1 vs placebowk 12 · n 31NCT05772520
5 other results
  • 44.8% vs 21.4% wk 12 · n 29 · Phase 2 · primary NCT05772520
  • 50% vs 21.4% wk 12 · n 8 · Phase 2 · primary NCT05772520
  • 50% vs 25% wk 12 · n 18 · Phase 2 · primary NCT05772520
  • 61.1% vs 25% wk 12 · n 18 · Phase 2 · primary NCT05772520
  • 50% vs 25% wk 12 · n 8 · Phase 2 · primary NCT05772520

PASI 90

brepocitinib
20% vs 4.3%+15.7 vs placebo60 mg Once Daily (QD) Followed by 30 mg QD · wk 16 · n 25NCT02969018
62 other results
  • 3.4% vs 4.3% 60 mg QD Followed by 10 mg QD · wk 16 · n 29 · Phase 2 · secondary NCT02969018
  • 15.4% vs 4.3% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 16 · n 26 · Phase 2 · secondary NCT02969018
  • 4% vs 4.3% 60 mg QD Followed by Placebo · wk 16 · n 25 · Phase 2 · secondary NCT02969018
  • 28% vs 4.3% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 14 · n 25 · Phase 2 · secondary NCT02969018
  • 13.8% vs 4.3% 60 mg QD Followed by 10 mg QD · wk 14 · n 29 · Phase 2 · secondary NCT02969018
  • 11.5% vs 4.3% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 14 · n 26 · Phase 2 · secondary NCT02969018
  • 8% vs 4.3% 60 mg QD Followed by Placebo · wk 14 · n 25 · Phase 2 · secondary NCT02969018
  • 36% vs 4.3% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 12 · n 25 · Phase 2 · secondary NCT02969018
  • 13.8% vs 4.3% 60 mg QD Followed by 10 mg QD · wk 12 · n 29 · Phase 2 · secondary NCT02969018
  • 26.9% vs 4.3% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 12 · n 26 · Phase 2 · secondary NCT02969018
  • 8% vs 4.3% 60 mg QD Followed by Placebo · wk 12 · n 25 · Phase 2 · secondary NCT02969018
  • 28% vs 4.3% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 10 · n 25 · Phase 2 · secondary NCT02969018
  • 17.2% vs 4.3% 60 mg QD Followed by 10 mg QD · wk 10 · n 29 · Phase 2 · secondary NCT02969018
  • 26.9% vs 4.3% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 10 · n 26 · Phase 2 · secondary NCT02969018
  • 8% vs 4.3% 60 mg QD Followed by Placebo · wk 10 · n 25 · Phase 2 · secondary NCT02969018
  • 24% vs 0% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 8 · n 25 · Phase 2 · secondary NCT02969018
  • 17.2% vs 0% 60 mg QD Followed by 10 mg QD · wk 8 · n 29 · Phase 2 · secondary NCT02969018
  • 30.8% vs 0% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 8 · n 26 · Phase 2 · secondary NCT02969018
  • 8% vs 0% 60 mg QD Followed by Placebo · wk 8 · n 25 · Phase 2 · secondary NCT02969018
  • 16% vs 0% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 6 · n 25 · Phase 2 · secondary NCT02969018
  • 20.7% vs 0% 60 mg QD Followed by 10 mg QD · wk 6 · n 29 · Phase 2 · secondary NCT02969018
  • 26.9% vs 0% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 6 · n 26 · Phase 2 · secondary NCT02969018
  • 12% vs 0% 60 mg QD Followed by Placebo · wk 6 · n 25 · Phase 2 · secondary NCT02969018
  • 12% vs 0% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 4 · n 25 · Phase 2 · secondary NCT02969018
  • 20.7% vs 0% 60 mg QD Followed by 10 mg QD · wk 4 · n 29 · Phase 2 · secondary NCT02969018
  • 42.3% vs 0% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 4 · n 26 · Phase 2 · secondary NCT02969018
  • 16% vs 0% 60 mg QD Followed by Placebo · wk 4 · n 25 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 2 · n 25 · Phase 2 · secondary NCT02969018
  • 3.4% vs 0% 60 mg QD Followed by 10 mg QD · wk 2 · n 29 · Phase 2 · secondary NCT02969018
  • 7.7% vs 0% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 2 · n 26 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 60 mg QD Followed by Placebo · wk 2 · n 25 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 60 mg Once Daily (QD) Followed by 30 mg QD · wk 1 · n 25 · Phase 2 · secondary NCT02969018
  • 3.4% vs 0% 60 mg QD Followed by 10 mg QD · wk 1 · n 29 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 60 mg QD Followed by 100 mg Once Weekly (QW) · wk 1 · n 26 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 60 mg QD Followed by Placebo · wk 1 · n 25 · Phase 2 · secondary NCT02969018
  • 27.6% vs 4.3% 30 mg QD · wk 16 · n 29 · Phase 2 · secondary NCT02969018
  • 8% vs 4.3% 30 mg QD Followed by 10 mg QD · wk 16 · n 25 · Phase 2 · secondary NCT02969018
  • 10% vs 4.3% 30 mg QD Followed by 100 mg QW · wk 16 · n 30 · Phase 2 · secondary NCT02969018
  • 37.9% vs 4.3% 30 mg QD · wk 14 · n 29 · Phase 2 · secondary NCT02969018
  • 4% vs 4.3% 30 mg QD Followed by 10 mg QD · wk 14 · n 25 · Phase 2 · secondary NCT02969018
  • 13.3% vs 4.3% 30 mg QD Followed by 100 mg QW · wk 14 · n 30 · Phase 2 · secondary NCT02969018
  • 51.7% vs 4.3% 30 mg QD · wk 12 · n 29 · Phase 2 · secondary NCT02969018
  • 8% vs 4.3% 30 mg QD Followed by 10 mg QD · wk 12 · n 25 · Phase 2 · secondary NCT02969018
  • 10% vs 4.3% 30 mg QD Followed by 100 mg QW · wk 12 · n 30 · Phase 2 · secondary NCT02969018
  • 34.5% vs 4.3% 30 mg QD · wk 10 · n 29 · Phase 2 · secondary NCT02969018
  • 8% vs 4.3% 30 mg QD Followed by 10 mg QD · wk 10 · n 25 · Phase 2 · secondary NCT02969018
  • 13.3% vs 4.3% 30 mg QD Followed by 100 mg QW · wk 10 · n 30 · Phase 2 · secondary NCT02969018
  • 34.5% vs 0% 30 mg QD · wk 8 · n 29 · Phase 2 · secondary NCT02969018
  • 4% vs 0% 30 mg QD Followed by 10 mg QD · wk 8 · n 25 · Phase 2 · secondary NCT02969018
  • 16.7% vs 0% 30 mg QD Followed by 100 mg QW · wk 8 · n 30 · Phase 2 · secondary NCT02969018
  • 24.1% vs 0% 30 mg QD · wk 6 · n 29 · Phase 2 · secondary NCT02969018
  • 8% vs 0% 30 mg QD Followed by 10 mg QD · wk 6 · n 25 · Phase 2 · secondary NCT02969018
  • 20% vs 0% 30 mg QD Followed by 100 mg QW · wk 6 · n 30 · Phase 2 · secondary NCT02969018
  • 6.9% vs 0% 30 mg QD · wk 4 · n 29 · Phase 2 · secondary NCT02969018
  • 8% vs 0% 30 mg QD Followed by 10 mg QD · wk 4 · n 25 · Phase 2 · secondary NCT02969018
  • 3.3% vs 0% 30 mg QD Followed by 100 mg QW · wk 4 · n 30 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 30 mg QD · wk 2 · n 29 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 30 mg QD Followed by 10 mg QD · wk 2 · n 25 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 30 mg QD Followed by 100 mg QW · wk 2 · n 30 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 30 mg QD · wk 1 · n 29 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 30 mg QD Followed by 10 mg QD · wk 1 · n 25 · Phase 2 · secondary NCT02969018
  • 0% vs 0% 30 mg QD Followed by 100 mg QW · wk 1 · n 30 · Phase 2 · secondary NCT02969018
Girocitinib
—Not reported

PASI 100

brepocitinib
—Not reported
Girocitinib
—Not reported

sPGA 0/1

brepocitinib
11.4% vs 8.2%+3.2 vs placebo0.1% QD · wk 16 · n 37NCT03850483
62 other results
  • 8.6% vs 8.2% 0.3% QD · wk 16 · n 37 · Phase 2 · secondary NCT03850483
  • 14.3% vs 8.2% 1.0% QD · wk 16 · n 36 · Phase 2 · secondary NCT03850483
  • 16.2% vs 8.2% 3.0% QD · wk 16 · n 37 · Phase 2 · secondary NCT03850483
  • 14.7% vs 8.2% 0.3% BID · wk 16 · n 36 · Phase 2 · secondary NCT03850483
  • 11.8% vs 8.2% 1.0% BID · wk 16 · n 35 · Phase 2 · secondary NCT03850483
  • 16.2% vs 8.2% 3.0% BID · wk 16 · n 38 · Phase 2 · secondary NCT03850483
  • 13.5% vs 6.3% 0.1% QD · wk 14 · n 37 · Phase 2 · secondary NCT03850483
  • 5.6% vs 6.3% 0.3% QD · wk 14 · n 37 · Phase 2 · secondary NCT03850483
  • 8.6% vs 6.3% 1.0% QD · wk 14 · n 36 · Phase 2 · secondary NCT03850483
  • 13.5% vs 6.3% 3.0% QD · wk 14 · n 37 · Phase 2 · secondary NCT03850483
  • 8.8% vs 6.3% 0.3% BID · wk 14 · n 36 · Phase 2 · secondary NCT03850483
  • 11.8% vs 6.3% 1.0% BID · wk 14 · n 35 · Phase 2 · secondary NCT03850483
  • 8.1% vs 6.3% 3.0% BID · wk 14 · n 38 · Phase 2 · secondary NCT03850483
  • 10.3% vs 14.7% 0.1% QD · wk 12 · n 29 · Phase 2 · secondary NCT03850483
  • 15.4% vs 14.7% 0.3% QD · wk 12 · n 26 · Phase 2 · secondary NCT03850483
  • 10.3% vs 14.7% 1.0% QD · wk 12 · n 29 · Phase 2 · secondary NCT03850483
  • 21.4% vs 14.7% 3.0% QD · wk 12 · n 28 · Phase 2 · secondary NCT03850483
  • 20.8% vs 14.7% 0.3% BID · wk 12 · n 24 · Phase 2 · secondary NCT03850483
  • 27.6% vs 14.7% 1.0% BID · wk 12 · n 29 · Phase 2 · secondary NCT03850483
  • 17.9% vs 14.7% 3.0% BID · wk 12 · n 28 · Phase 2 · secondary NCT03850483
  • 5.4% vs 16.3% 0.1% QD · wk 10 · n 37 · Phase 2 · secondary NCT03850483
  • 8.1% vs 16.3% 0.3% QD · wk 10 · n 37 · Phase 2 · secondary NCT03850483
  • 8.3% vs 16.3% 1.0% QD · wk 10 · n 36 · Phase 2 · secondary NCT03850483
  • 16.2% vs 16.3% 3.0% QD · wk 10 · n 37 · Phase 2 · secondary NCT03850483
  • 16.7% vs 16.3% 0.3% BID · wk 10 · n 36 · Phase 2 · secondary NCT03850483
  • 8.6% vs 16.3% 1.0% BID · wk 10 · n 35 · Phase 2 · secondary NCT03850483
  • 13.2% vs 16.3% 3.0% BID · wk 10 · n 38 · Phase 2 · secondary NCT03850483
  • 5.4% vs 6.1% 0.1% QD · wk 8 · n 37 · Phase 2 · secondary NCT03850483
  • 5.4% vs 6.1% 0.3% QD · wk 8 · n 37 · Phase 2 · secondary NCT03850483
  • 2.8% vs 6.1% 1.0% QD · wk 8 · n 36 · Phase 2 · secondary NCT03850483
  • 10.8% vs 6.1% 3.0% QD · wk 8 · n 37 · Phase 2 · secondary NCT03850483
  • 13.9% vs 6.1% 0.3% BID · wk 8 · n 36 · Phase 2 · secondary NCT03850483
  • 5.7% vs 6.1% 1.0% BID · wk 8 · n 35 · Phase 2 · secondary NCT03850483
  • 18.4% vs 6.1% 3.0% BID · wk 8 · n 38 · Phase 2 · secondary NCT03850483
  • 5.4% vs 8.2% 0.1% QD · wk 6 · n 37 · Phase 2 · secondary NCT03850483
  • 2.7% vs 8.2% 0.3% QD · wk 6 · n 37 · Phase 2 · secondary NCT03850483
  • 8.3% vs 8.2% 1.0% QD · wk 6 · n 36 · Phase 2 · secondary NCT03850483
  • 13.5% vs 8.2% 3.0% QD · wk 6 · n 37 · Phase 2 · secondary NCT03850483
  • 8.3% vs 8.2% 0.3% BID · wk 6 · n 36 · Phase 2 · secondary NCT03850483
  • 5.7% vs 8.2% 1.0% BID · wk 6 · n 35 · Phase 2 · secondary NCT03850483
  • 13.2% vs 8.2% 3.0% BID · wk 6 · n 38 · Phase 2 · secondary NCT03850483
  • 5.4% vs 8.2% 0.1% QD · wk 4 · n 37 · Phase 2 · secondary NCT03850483
  • 0% vs 8.2% 0.3% QD · wk 4 · n 37 · Phase 2 · secondary NCT03850483
  • 5.6% vs 8.2% 1.0% QD · wk 4 · n 36 · Phase 2 · secondary NCT03850483
  • 5.4% vs 8.2% 3.0% QD · wk 4 · n 37 · Phase 2 · secondary NCT03850483
  • 8.3% vs 8.2% 0.3% BID · wk 4 · n 36 · Phase 2 · secondary NCT03850483
  • 11.4% vs 8.2% 1.0% BID · wk 4 · n 35 · Phase 2 · secondary NCT03850483
  • 21.1% vs 8.2% 3.0% BID · wk 4 · n 38 · Phase 2 · secondary NCT03850483
  • 0% vs 2% 0.1% QD · wk 2 · n 37 · Phase 2 · secondary NCT03850483
  • 0% vs 2% 0.3% QD · wk 2 · n 37 · Phase 2 · secondary NCT03850483
  • 2.8% vs 2% 1.0% QD · wk 2 · n 36 · Phase 2 · secondary NCT03850483
  • 2.7% vs 2% 3.0% QD · wk 2 · n 37 · Phase 2 · secondary NCT03850483
  • 0% vs 2% 0.3% BID · wk 2 · n 36 · Phase 2 · secondary NCT03850483
  • 5.7% vs 2% 1.0% BID · wk 2 · n 35 · Phase 2 · secondary NCT03850483
  • 10.5% vs 2% 3.0% BID · wk 2 · n 38 · Phase 2 · secondary NCT03850483
  • 2.7% vs 0% 0.1% QD · wk 1 · n 37 · Phase 2 · secondary NCT03850483
  • 2.7% vs 0% 0.3% QD · wk 1 · n 37 · Phase 2 · secondary NCT03850483
  • 0% vs 0% 1.0% QD · wk 1 · n 36 · Phase 2 · secondary NCT03850483
  • 0% vs 0% 3.0% QD · wk 1 · n 37 · Phase 2 · secondary NCT03850483
  • 0% vs 0% 0.3% BID · wk 1 · n 36 · Phase 2 · secondary NCT03850483
  • 5.7% vs 0% 1.0% BID · wk 1 · n 35 · Phase 2 · secondary NCT03850483
  • 5.3% vs 0% 3.0% BID · wk 1 · n 38 · Phase 2 · secondary NCT03850483
Girocitinib
—Not reported

DLQI, change

brepocitinib
—Not reported
Girocitinib
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. brepocitinib: 4 of 4 rows · Girocitinib: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricbrepocitinibGirocitinib
Dropout rate
16%60 mg Once Daily (QD) Followed by 30 mg QDa
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
show 29 more results
27.6%60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
23.1%60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
20%60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
6.9%30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
32%30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
26.7%30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
—200 mg single dose
NCT02310750 · Phase 1
—175 mg once daily
NCT02310750 · Phase 1
—100 mg
NCT02310750 · Phase 1
—100 mg once daily
NCT02310750 · Phase 1
—100 mg single dose
NCT02310750 · Phase 1
—100 mg solution fasted
NCT02310750 · Phase 1
—100 mg tablet fasted
NCT02310750 · Phase 1
—100 mg tablet fed
NCT02310750 · Phase 1
—50 mg twice daily
NCT02310750 · Phase 1
—30 mg
NCT02310750 · Phase 1
—30 mg once daily
NCT02310750 · Phase 1
—30 mg single dose
NCT02310750 · Phase 1
—10 mg once daily
NCT02310750 · Phase 1
—10 mg single dose
NCT02310750 · Phase 1
0%3 mg single dose
NCT02310750 · Phase 1
14.3%1 mg single dose
NCT02310750 · Phase 1
—0.1% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
—0.3% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
—0.3% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
—1.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
—1.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
—3.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
—3.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
22.6%Cohort 1
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
20.7%Cohort 2
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2
0%Cohort 3
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2
Discontinued due to AEs
8%60 mg Once Daily (QD) Followed by 30 mg QDa
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
show 29 more results
13.8%60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
3.8%60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
8%60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
0%30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
4%30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
6.7%30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
—200 mg single dose
NCT02310750 · Phase 1
—175 mg once daily
NCT02310750 · Phase 1
—100 mg
NCT02310750 · Phase 1
—100 mg once daily
NCT02310750 · Phase 1
—100 mg single dose
NCT02310750 · Phase 1
—100 mg solution fasted
NCT02310750 · Phase 1
—100 mg tablet fasted
NCT02310750 · Phase 1
—100 mg tablet fed
NCT02310750 · Phase 1
—50 mg twice daily
NCT02310750 · Phase 1
—30 mg
NCT02310750 · Phase 1
—30 mg once daily
NCT02310750 · Phase 1
—30 mg single dose
NCT02310750 · Phase 1
—10 mg once daily
NCT02310750 · Phase 1
—10 mg single dose
NCT02310750 · Phase 1
—3 mg single dose
NCT02310750 · Phase 1
—1 mg single dose
NCT02310750 · Phase 1
—0.1% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
—0.3% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
—0.3% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
—1.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
—1.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
—3.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
—3.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
—Cohort 1
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
—Cohort 2
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2
—Cohort 3
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2
Serious AEs
8%60 mg Once Daily (QD) Followed by 30 mg QDa
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
show 29 more results
3.4%60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
3.8%60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
4%60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
0%30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
0%30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
0%30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
0%200 mg single dose
NCT02310750 · Phase 1
0%175 mg once daily
NCT02310750 · Phase 1
0%100 mg
NCT02310750 · Phase 1
0%100 mg once daily
NCT02310750 · Phase 1
0%100 mg single dose
NCT02310750 · Phase 1
0%100 mg solution fasted
NCT02310750 · Phase 1
0%100 mg tablet fasted
NCT02310750 · Phase 1
0%100 mg tablet fed
NCT02310750 · Phase 1
0%50 mg twice daily
NCT02310750 · Phase 1
0%30 mg
NCT02310750 · Phase 1
0%30 mg once daily
NCT02310750 · Phase 1
0%30 mg single dose
NCT02310750 · Phase 1
0%10 mg once daily
NCT02310750 · Phase 1
0%10 mg single dose
NCT02310750 · Phase 1
0%3 mg single dose
NCT02310750 · Phase 1
0%1 mg single dose
NCT02310750 · Phase 1
0%0.1% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
2.8%0.3% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
0%0.3% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
5.6%1.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
2.8%1.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
0%3.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
0%3.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
0%Cohort 1
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
0%Cohort 2
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2
0%Cohort 3
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2
Most frequent reported AEs
60 mg Once Daily (QD) Followed by 30 mg QDa
nasopharyngitis 16% (placebo 13%)
upper respiratory tract infection 8% (placebo 4.3%)
arthralgia 4% (placebo 4.3%)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
show 29 more results
60 mg QD Followed by 10 mg QD
nasopharyngitis 10.3% (placebo 13%)
acne 6.9% (placebo 0%)
arthralgia 6.9% (placebo 4.3%)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
60 mg QD Followed by 100 mg Once Weekly (QW)
upper respiratory tract infection 19.2% (placebo 4.3%)
headache 11.5% (placebo 4.3%)
nasopharyngitis 11.5% (placebo 13%)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
60 mg QD Followed by Placebo
headache 12% (placebo 4.3%)
nasopharyngitis 12% (placebo 13%)
pruritus 12% (placebo 0%)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
30 mg QD
nasopharyngitis 17.2% (placebo 13%)
headache 13.8% (placebo 4.3%)
back pain 6.9% (placebo 8.7%)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
30 mg QD Followed by 10 mg QD
nasopharyngitis 24% (placebo 13%)
back pain 8% (placebo 8.7%)
ligament sprain 8% (placebo 0%)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
30 mg QD Followed by 100 mg QW
nasopharyngitis 13.3% (placebo 13%)
diarrhoea 10% (placebo 4.3%)
upper respiratory tract infection 10% (placebo 4.3%)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
200 mg single dose
blood creatinine increased 12.5% (placebo 11.1%)
headache 12.5% (placebo 0%)
abnormal dreams 0% (placebo 0%)
NCT02310750 · Phase 1
175 mg once daily
blood creatinine increased 66.7% (placebo 11.1%)
constipation 16.7% (placebo 33.3%)
neutropenia 16.7% (placebo 0%)
NCT02310750 · Phase 1
100 mg
blood creatinine increased 85.7% (placebo 11.1%)
flushing 14.3% (placebo 0%)
headache 14.3% (placebo 0%)
NCT02310750 · Phase 1
100 mg once daily
blood creatinine increased 16.7% (placebo 11.1%)
headache 16.7% (placebo 0%)
upper respiratory tract infection 16.7% (placebo 0%)
NCT02310750 · Phase 1
100 mg single dose
blood creatinine increased 12.5% (placebo 11.1%)
constipation 12.5% (placebo 33.3%)
dizziness 12.5% (placebo 0%)
NCT02310750 · Phase 1
100 mg solution fasted
headache 8.3% (placebo 0%)
nausea 8.3% (placebo 0%)
abnormal dreams 0% (placebo 0%)
NCT02310750 · Phase 1
100 mg tablet fasted
contusion 8.3% (placebo 0%)
abnormal dreams 0% (placebo 0%)
blood creatinine increased 0% (placebo 11.1%)
NCT02310750 · Phase 1
100 mg tablet fed
abnormal dreams 0% (placebo 0%)
blood creatinine increased 0% (placebo 11.1%)
constipation 0% (placebo 33.3%)
NCT02310750 · Phase 1
50 mg twice daily
blood creatinine increased 80% (placebo 11.1%)
neutrophil count decreased 40% (placebo 0%)
abnormal dreams 0% (placebo 0%)
NCT02310750 · Phase 1
30 mg
blood creatinine increased 50% (placebo 11.1%)
constipation 21.4% (placebo 33.3%)
abnormal dreams 7.1% (placebo 0%)
NCT02310750 · Phase 1
30 mg once daily
blood creatinine increased 25% (placebo 11.1%)
presyncope 25% (placebo 0%)
abnormal dreams 0% (placebo 0%)
NCT02310750 · Phase 1
30 mg single dose
haematoma 16.7% (placebo 0%)
abnormal dreams 0% (placebo 0%)
blood creatinine increased 0% (placebo 11.1%)
NCT02310750 · Phase 1
10 mg once daily
blood creatinine increased 20% (placebo 11.1%)
syncope 20% (placebo 0%)
upper respiratory tract infection 20% (placebo 0%)
NCT02310750 · Phase 1
10 mg single dose
abnormal dreams 0% (placebo 0%)
blood creatinine increased 0% (placebo 11.1%)
constipation 0% (placebo 33.3%)
NCT02310750 · Phase 1
3 mg single dose
headache 16.7% (placebo 0%)
abnormal dreams 0% (placebo 0%)
blood creatinine increased 0% (placebo 11.1%)
NCT02310750 · Phase 1
1 mg single dose
urine flow decreased 14.3% (placebo 0%)
abnormal dreams 0% (placebo 0%)
blood creatinine increased 0% (placebo 11.1%)
NCT02310750 · Phase 1
0.1% QD
nasopharyngitis 8.1% (placebo 6.1%)
headache 5.4% (placebo 0%)
upper respiratory tract infection 5.4% (placebo 4.1%)
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
0.3% BID
cough 5.6% (placebo 4.1%)
headache 2.8% (placebo 0%)
nasopharyngitis 2.8% (placebo 6.1%)
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
0.3% QD
cough 5.4% (placebo 4.1%)
rhinitis 5.4% (placebo 2%)
hypertension 2.7% (placebo 4.1%)
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
1.0% BID
nasopharyngitis 19.4% (placebo 6.1%)
cough 5.6% (placebo 4.1%)
hypertension 5.6% (placebo 4.1%)
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
1.0% QD
nasopharyngitis 16.7% (placebo 6.1%)
blood creatine phosphokinase increased 5.6% (placebo 0%)
cough 2.8% (placebo 4.1%)
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
3.0% BID
hypertension 2.6% (placebo 4.1%)
pruritus 2.6% (placebo 2%)
upper respiratory tract infection 2.6% (placebo 4.1%)
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
3.0% QD
nasopharyngitis 8.1% (placebo 6.1%)
hypertension 5.4% (placebo 4.1%)
upper respiratory tract infection 5.4% (placebo 4.1%)
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
alanine aminotransferase increased 6.5% (placebo 7.1%)
headache 6.5% (placebo 0%)
leukopenia 6.5% (placebo 0%)
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
alanine aminotransferase increased 10.3% (placebo 7.1%)
aspartate aminotransferase increased 6.9% (placebo 0%)
neutropenia 6.9% (placebo 0%)
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2
nasopharyngitis 12.5% (placebo 0%)
activated partial thromboplastin time prolonged 0% (placebo 7.1%)
alanine aminotransferase increased 0% (placebo 7.1%)
NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2

Notes

  1. aPopulation comparability has not been reviewed for 16 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

brepocitinib

PASI -15.85 vs -7.21 placebo score @ 12wk60 mg Once Daily (QD) Followed by 30 mg QD
absolute change · score
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
show 64 more results
-10.56 vs -7.21 placebo score @ 12wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-14.28 vs -7.21 placebo score @ 12wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-10.14 vs -7.21 placebo score @ 12wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-13.17 vs -4.17 placebo score @ 4wk60 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-5.74 vs -1.35 placebo score @ 1wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-4.6 vs -1.35 placebo score @ 1wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-5.85 vs -1.35 placebo score @ 1wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-5.37 vs -1.35 placebo score @ 1wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-9.44 vs -2.28 placebo score @ 2wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-8.35 vs -2.28 placebo score @ 2wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-10.79 vs -2.28 placebo score @ 2wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-9.49 vs -2.28 placebo score @ 2wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-12.85 vs -4.02 placebo score @ 4wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-12.19 vs -4.02 placebo score @ 4wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-14.11 vs -4.02 placebo score @ 4wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-13.91 vs -4.02 placebo score @ 4wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-15 vs -5.52 placebo score @ 6wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-12.12 vs -5.52 placebo score @ 6wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-15 vs -5.52 placebo score @ 6wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-13.85 vs -5.52 placebo score @ 6wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-15.94 vs -6.56 placebo score @ 8wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-11.09 vs -6.56 placebo score @ 8wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-14.97 vs -6.56 placebo score @ 8wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-12.87 vs -6.56 placebo score @ 8wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-16.54 vs -6.78 placebo score @ 10wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-9.89 vs -6.78 placebo score @ 10wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-15.52 vs -6.78 placebo score @ 10wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-11.64 vs -6.78 placebo score @ 10wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-15.47 vs -6.98 placebo score @ 14wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-8.11 vs -6.98 placebo score @ 14wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-13.31 vs -6.98 placebo score @ 14wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-9.45 vs -6.98 placebo score @ 14wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-14.16 vs -6.76 placebo score @ 16wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-6.59 vs -6.76 placebo score @ 16wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-13 vs -6.76 placebo score @ 16wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-7.83 vs -6.76 placebo score @ 16wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-17.28 vs -7.21 placebo score @ 12wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-13.27 vs -7.21 placebo score @ 12wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-11.88 vs -7.21 placebo score @ 12wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-12.16 vs -4.17 placebo score @ 4wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-3.97 vs -1.35 placebo score @ 1wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-4.41 vs -1.35 placebo score @ 1wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-3.46 vs -1.35 placebo score @ 1wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-7.86 vs -2.28 placebo score @ 2wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-7.79 vs -2.28 placebo score @ 2wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-7.93 vs -2.28 placebo score @ 2wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-11.72 vs -4.02 placebo score @ 4wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-12.88 vs -4.02 placebo score @ 4wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-13.06 vs -4.02 placebo score @ 4wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-14.3 vs -5.52 placebo score @ 6wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-14.33 vs -5.52 placebo score @ 6wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-14.17 vs -5.52 placebo score @ 6wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-15.82 vs -6.56 placebo score @ 8wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-14.27 vs -6.56 placebo score @ 8wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-13.83 vs -6.56 placebo score @ 8wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-16.65 vs -6.78 placebo score @ 10wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-14.98 vs -6.78 placebo score @ 10wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-12.97 vs -6.78 placebo score @ 10wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-16.14 vs -6.98 placebo score @ 14wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-10.44 vs -6.98 placebo score @ 14wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-11.03 vs -6.98 placebo score @ 14wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-14.38 vs -6.76 placebo score @ 16wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-9.62 vs -6.76 placebo score @ 16wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-9.13 vs -6.76 placebo score @ 16wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
PASI 50 12% (n=25) vs 0% (n=23) placebo @ 1wk60 mg Once Daily (QD) Followed by 30 mg QD
responder rate · % of participants
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
show 62 more results
13.8% (n=29) vs 0% (n=23) placebo @ 1wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
19.2% (n=26) vs 0% (n=23) placebo @ 1wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
20% (n=25) vs 0% (n=23) placebo @ 1wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
44% (n=25) vs 0% (n=23) placebo @ 2wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
37.9% (n=29) vs 0% (n=23) placebo @ 2wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
46.2% (n=26) vs 0% (n=23) placebo @ 2wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
32% (n=25) vs 0% (n=23) placebo @ 2wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
60% (n=25) vs 13% (n=23) placebo @ 4wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
69% (n=29) vs 13% (n=23) placebo @ 4wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
69.2% (n=26) vs 13% (n=23) placebo @ 4wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
68% (n=25) vs 13% (n=23) placebo @ 4wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
72% (n=25) vs 26.1% (n=23) placebo @ 6wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
62.1% (n=29) vs 26.1% (n=23) placebo @ 6wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
73.1% (n=26) vs 26.1% (n=23) placebo @ 6wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
68% (n=25) vs 26.1% (n=23) placebo @ 6wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
72% (n=25) vs 17.4% (n=23) placebo @ 8wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
55.2% (n=29) vs 17.4% (n=23) placebo @ 8wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
73.1% (n=26) vs 17.4% (n=23) placebo @ 8wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
52% (n=25) vs 17.4% (n=23) placebo @ 8wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
68% (n=25) vs 17.4% (n=23) placebo @ 10wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
44.8% (n=29) vs 17.4% (n=23) placebo @ 10wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
73.1% (n=26) vs 17.4% (n=23) placebo @ 10wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
48% (n=25) vs 17.4% (n=23) placebo @ 10wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
68% (n=25) vs 21.7% (n=23) placebo @ 12wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
44.8% (n=29) vs 21.7% (n=23) placebo @ 12wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
69.2% (n=26) vs 21.7% (n=23) placebo @ 12wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
52% (n=25) vs 21.7% (n=23) placebo @ 12wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
64% (n=25) vs 26.1% (n=23) placebo @ 14wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
44.8% (n=29) vs 26.1% (n=23) placebo @ 14wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
61.5% (n=26) vs 26.1% (n=23) placebo @ 14wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
48% (n=25) vs 26.1% (n=23) placebo @ 14wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
60% (n=25) vs 21.7% (n=23) placebo @ 16wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
34.5% (n=29) vs 21.7% (n=23) placebo @ 16wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
53.8% (n=26) vs 21.7% (n=23) placebo @ 16wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
40% (n=25) vs 21.7% (n=23) placebo @ 16wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
10.3% (n=29) vs 0% (n=23) placebo @ 1wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
8% (n=25) vs 0% (n=23) placebo @ 1wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
3.3% (n=30) vs 0% (n=23) placebo @ 1wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
41.4% (n=29) vs 0% (n=23) placebo @ 2wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
20% (n=25) vs 0% (n=23) placebo @ 2wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
33.3% (n=30) vs 0% (n=23) placebo @ 2wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
69% (n=29) vs 13% (n=23) placebo @ 4wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
60% (n=25) vs 13% (n=23) placebo @ 4wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
66.7% (n=30) vs 13% (n=23) placebo @ 4wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
82.8% (n=29) vs 26.1% (n=23) placebo @ 6wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
60% (n=25) vs 26.1% (n=23) placebo @ 6wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
63.3% (n=30) vs 26.1% (n=23) placebo @ 6wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
86.2% (n=29) vs 17.4% (n=23) placebo @ 8wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
56% (n=25) vs 17.4% (n=23) placebo @ 8wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
63.3% (n=30) vs 17.4% (n=23) placebo @ 8wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
86.2% (n=29) vs 17.4% (n=23) placebo @ 10wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
48% (n=25) vs 17.4% (n=23) placebo @ 10wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
56.7% (n=30) vs 17.4% (n=23) placebo @ 10wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
89.7% (n=29) vs 21.7% (n=23) placebo @ 12wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
48% (n=25) vs 21.7% (n=23) placebo @ 12wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
53.3% (n=30) vs 21.7% (n=23) placebo @ 12wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
89.7% (n=29) vs 26.1% (n=23) placebo @ 14wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
36% (n=25) vs 26.1% (n=23) placebo @ 14wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
36.7% (n=30) vs 26.1% (n=23) placebo @ 14wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
79.3% (n=29) vs 21.7% (n=23) placebo @ 16wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
40% (n=25) vs 21.7% (n=23) placebo @ 16wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
36.7% (n=30) vs 21.7% (n=23) placebo @ 16wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
PASI 90 0% (n=25) vs 0% (n=23) placebo @ 1wk60 mg Once Daily (QD) Followed by 30 mg QD
responder rate · % of participants
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
show 62 more results
3.4% (n=29) vs 0% (n=23) placebo @ 1wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=26) vs 0% (n=23) placebo @ 1wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=25) vs 0% (n=23) placebo @ 1wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=25) vs 0% (n=23) placebo @ 2wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
3.4% (n=29) vs 0% (n=23) placebo @ 2wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
7.7% (n=26) vs 0% (n=23) placebo @ 2wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=25) vs 0% (n=23) placebo @ 2wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
12% (n=25) vs 0% (n=23) placebo @ 4wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
20.7% (n=29) vs 0% (n=23) placebo @ 4wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
42.3% (n=26) vs 0% (n=23) placebo @ 4wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
16% (n=25) vs 0% (n=23) placebo @ 4wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
16% (n=25) vs 0% (n=23) placebo @ 6wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
20.7% (n=29) vs 0% (n=23) placebo @ 6wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
26.9% (n=26) vs 0% (n=23) placebo @ 6wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
12% (n=25) vs 0% (n=23) placebo @ 6wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
24% (n=25) vs 0% (n=23) placebo @ 8wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
17.2% (n=29) vs 0% (n=23) placebo @ 8wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
30.8% (n=26) vs 0% (n=23) placebo @ 8wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
8% (n=25) vs 0% (n=23) placebo @ 8wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
28% (n=25) vs 4.3% (n=23) placebo @ 10wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
17.2% (n=29) vs 4.3% (n=23) placebo @ 10wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
26.9% (n=26) vs 4.3% (n=23) placebo @ 10wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
8% (n=25) vs 4.3% (n=23) placebo @ 10wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
36% (n=25) vs 4.3% (n=23) placebo @ 12wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
13.8% (n=29) vs 4.3% (n=23) placebo @ 12wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
26.9% (n=26) vs 4.3% (n=23) placebo @ 12wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
8% (n=25) vs 4.3% (n=23) placebo @ 12wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
28% (n=25) vs 4.3% (n=23) placebo @ 14wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
13.8% (n=29) vs 4.3% (n=23) placebo @ 14wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
11.5% (n=26) vs 4.3% (n=23) placebo @ 14wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
8% (n=25) vs 4.3% (n=23) placebo @ 14wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
20% (n=25) vs 4.3% (n=23) placebo @ 16wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
3.4% (n=29) vs 4.3% (n=23) placebo @ 16wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
15.4% (n=26) vs 4.3% (n=23) placebo @ 16wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
4% (n=25) vs 4.3% (n=23) placebo @ 16wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=29) vs 0% (n=23) placebo @ 1wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=25) vs 0% (n=23) placebo @ 1wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=30) vs 0% (n=23) placebo @ 1wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=29) vs 0% (n=23) placebo @ 2wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=25) vs 0% (n=23) placebo @ 2wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=30) vs 0% (n=23) placebo @ 2wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
6.9% (n=29) vs 0% (n=23) placebo @ 4wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
8% (n=25) vs 0% (n=23) placebo @ 4wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
3.3% (n=30) vs 0% (n=23) placebo @ 4wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
24.1% (n=29) vs 0% (n=23) placebo @ 6wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
8% (n=25) vs 0% (n=23) placebo @ 6wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
20% (n=30) vs 0% (n=23) placebo @ 6wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
34.5% (n=29) vs 0% (n=23) placebo @ 8wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
4% (n=25) vs 0% (n=23) placebo @ 8wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
16.7% (n=30) vs 0% (n=23) placebo @ 8wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
34.5% (n=29) vs 4.3% (n=23) placebo @ 10wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
8% (n=25) vs 4.3% (n=23) placebo @ 10wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
13.3% (n=30) vs 4.3% (n=23) placebo @ 10wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
51.7% (n=29) vs 4.3% (n=23) placebo @ 12wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
8% (n=25) vs 4.3% (n=23) placebo @ 12wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
10% (n=30) vs 4.3% (n=23) placebo @ 12wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
37.9% (n=29) vs 4.3% (n=23) placebo @ 14wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
4% (n=25) vs 4.3% (n=23) placebo @ 14wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
13.3% (n=30) vs 4.3% (n=23) placebo @ 14wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
27.6% (n=29) vs 4.3% (n=23) placebo @ 16wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
8% (n=25) vs 4.3% (n=23) placebo @ 16wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
10% (n=30) vs 4.3% (n=23) placebo @ 16wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
PASI -26.7% (n=25) vs -6.9% (n=23) placebo @ 1wk60 mg Once Daily (QD) Followed by 30 mg QD
percent change · % of baseline
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
show 125 more results
-24.66% (n=29) vs -6.9% (n=23) placebo @ 1wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-30.25% (n=26) vs -6.9% (n=23) placebo @ 1wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-23.33% (n=25) vs -6.9% (n=23) placebo @ 1wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-43.66% (n=25) vs -12.81% (n=23) placebo @ 2wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-44.17% (n=29) vs -12.81% (n=23) placebo @ 2wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-54.27% (n=26) vs -12.81% (n=23) placebo @ 2wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-42.58% (n=25) vs -12.81% (n=23) placebo @ 2wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-57.16% (n=25) vs -25.17% (n=23) placebo @ 4wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-63.02% (n=29) vs -25.17% (n=23) placebo @ 4wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-72.41% (n=26) vs -25.17% (n=23) placebo @ 4wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-64.71% (n=25) vs -25.17% (n=23) placebo @ 4wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-66.07% (n=25) vs -33.49% (n=23) placebo @ 6wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-63.31% (n=29) vs -33.49% (n=23) placebo @ 6wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-75.96% (n=26) vs -33.49% (n=23) placebo @ 6wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-65.06% (n=25) vs -33.49% (n=23) placebo @ 6wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-70.11% (n=25) vs -37.76% (n=23) placebo @ 8wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-62.25% (n=29) vs -37.76% (n=23) placebo @ 8wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-77.05% (n=26) vs -37.76% (n=23) placebo @ 8wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-59.88% (n=25) vs -37.76% (n=23) placebo @ 8wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-70.72% (n=25) vs -39.68% (n=23) placebo @ 10wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-57.55% (n=29) vs -39.68% (n=23) placebo @ 10wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-78.46% (n=26) vs -39.68% (n=23) placebo @ 10wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-53.81% (n=25) vs -39.68% (n=23) placebo @ 10wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-71.94% (n=25) vs -40.27% (n=23) placebo @ 12wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-58.52% (n=29) vs -40.27% (n=23) placebo @ 12wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-74.42% (n=26) vs -40.27% (n=23) placebo @ 12wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-51.49% (n=25) vs -40.27% (n=23) placebo @ 12wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-64.15% (n=25) vs -39.48% (n=23) placebo @ 14wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-47.87% (n=29) vs -39.48% (n=23) placebo @ 14wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-63.2% (n=26) vs -39.48% (n=23) placebo @ 14wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-44.3% (n=25) vs -39.48% (n=23) placebo @ 14wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-57.28% (n=25) vs -38.79% (n=23) placebo @ 16wk60 mg Once Daily (QD) Followed by 30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-38.48% (n=29) vs -38.79% (n=23) placebo @ 16wk60 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-60.56% (n=26) vs -38.79% (n=23) placebo @ 16wk60 mg QD Followed by 100 mg Once Weekly (QW)
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-36.63% (n=25) vs -38.79% (n=23) placebo @ 16wk60 mg QD Followed by Placebo
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-20.92% (n=29) vs -6.9% (n=23) placebo @ 1wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-17.5% (n=25) vs -6.9% (n=23) placebo @ 1wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-15.42% (n=30) vs -6.9% (n=23) placebo @ 1wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-40.89% (n=29) vs -12.81% (n=23) placebo @ 2wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-32.46% (n=25) vs -12.81% (n=23) placebo @ 2wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-35.89% (n=30) vs -12.81% (n=23) placebo @ 2wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-60.76% (n=29) vs -25.17% (n=23) placebo @ 4wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-53.93% (n=25) vs -25.17% (n=23) placebo @ 4wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-58.99% (n=30) vs -25.17% (n=23) placebo @ 4wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-73.91% (n=29) vs -33.49% (n=23) placebo @ 6wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-58.57% (n=25) vs -33.49% (n=23) placebo @ 6wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-63.17% (n=30) vs -33.49% (n=23) placebo @ 6wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-81.04% (n=29) vs -37.76% (n=23) placebo @ 8wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-58.32% (n=25) vs -37.76% (n=23) placebo @ 8wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-61.38% (n=30) vs -37.76% (n=23) placebo @ 8wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-84.82% (n=29) vs -39.68% (n=23) placebo @ 10wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-61.23% (n=25) vs -39.68% (n=23) placebo @ 10wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-57.24% (n=30) vs -39.68% (n=23) placebo @ 10wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-88.68% (n=29) vs -40.27% (n=23) placebo @ 12wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-57.81% (n=25) vs -40.27% (n=23) placebo @ 12wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-58.57% (n=30) vs -40.27% (n=23) placebo @ 12wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-83.39% (n=29) vs -39.48% (n=23) placebo @ 14wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-47.84% (n=25) vs -39.48% (n=23) placebo @ 14wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-47.52% (n=30) vs -39.48% (n=23) placebo @ 14wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-74.18% (n=29) vs -38.79% (n=23) placebo @ 16wk30 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-44.58% (n=25) vs -38.79% (n=23) placebo @ 16wk30 mg QD Followed by 10 mg QD
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-42.29% (n=30) vs -38.79% (n=23) placebo @ 16wk30 mg QD Followed by 100 mg QW
NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2
-12.9% (n=36) vs -15.5% (n=32) placebo @ 1wk0.1% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-8.2% (n=34) vs -15.5% (n=32) placebo @ 1wk0.3% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-10.4% (n=35) vs -15.5% (n=32) placebo @ 1wk1.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-13% (n=35) vs -15.5% (n=32) placebo @ 1wk3.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-9% (n=35) vs -15.5% (n=32) placebo @ 1wk0.3% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-13.7% (n=34) vs -15.5% (n=32) placebo @ 1wk1.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-13.5% (n=37) vs -15.5% (n=32) placebo @ 1wk3.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-12.4% (n=36) vs -21.6% (n=32) placebo @ 2wk0.1% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-12.6% (n=34) vs -21.6% (n=32) placebo @ 2wk0.3% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-17.9% (n=35) vs -21.6% (n=32) placebo @ 2wk1.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-19.8% (n=35) vs -21.6% (n=32) placebo @ 2wk3.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-20.7% (n=35) vs -21.6% (n=32) placebo @ 2wk0.3% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-23.3% (n=34) vs -21.6% (n=32) placebo @ 2wk1.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-24.7% (n=37) vs -21.6% (n=32) placebo @ 2wk3.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-20.5% (n=36) vs -24.1% (n=32) placebo @ 4wk0.1% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-15.6% (n=34) vs -24.1% (n=32) placebo @ 4wk0.3% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-17.6% (n=35) vs -24.1% (n=32) placebo @ 4wk1.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-25.1% (n=35) vs -24.1% (n=32) placebo @ 4wk3.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-33.9% (n=35) vs -24.1% (n=32) placebo @ 4wk0.3% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-24.1% (n=34) vs -24.1% (n=32) placebo @ 4wk1.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-29.2% (n=37) vs -24.1% (n=32) placebo @ 4wk3.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-20.3% (n=36) vs -23.7% (n=32) placebo @ 6wk0.1% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-18.4% (n=34) vs -23.7% (n=32) placebo @ 6wk0.3% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-21.8% (n=35) vs -23.7% (n=32) placebo @ 6wk1.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-36% (n=35) vs -23.7% (n=32) placebo @ 6wk3.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-36.6% (n=35) vs -23.7% (n=32) placebo @ 6wk0.3% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-31.2% (n=34) vs -23.7% (n=32) placebo @ 6wk1.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-27.5% (n=37) vs -23.7% (n=32) placebo @ 6wk3.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-25.6% (n=36) vs -25.3% (n=32) placebo @ 8wk0.1% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-14.3% (n=34) vs -25.3% (n=32) placebo @ 8wk0.3% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-30.5% (n=35) vs -25.3% (n=32) placebo @ 8wk1.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-35.9% (n=35) vs -25.3% (n=32) placebo @ 8wk3.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-35.2% (n=35) vs -25.3% (n=32) placebo @ 8wk0.3% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-32.4% (n=34) vs -25.3% (n=32) placebo @ 8wk1.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-34.3% (n=37) vs -25.3% (n=32) placebo @ 8wk3.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-27.6% (n=36) vs -26.8% (n=32) placebo @ 10wk0.1% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-22.9% (n=34) vs -26.8% (n=32) placebo @ 10wk0.3% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-35.3% (n=35) vs -26.8% (n=32) placebo @ 10wk1.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-36.1% (n=35) vs -26.8% (n=32) placebo @ 10wk3.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-33.4% (n=35) vs -26.8% (n=32) placebo @ 10wk0.3% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-35.1% (n=34) vs -26.8% (n=32) placebo @ 10wk1.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-34.6% (n=37) vs -26.8% (n=32) placebo @ 10wk3.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-29.1% (n=36) vs -20% (n=32) placebo @ 12wk0.1% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-18.5% (n=34) vs -20% (n=32) placebo @ 12wk0.3% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-33.7% (n=35) vs -20% (n=32) placebo @ 12wk1.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-39% (n=35) vs -20% (n=32) placebo @ 12wk3.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-34.1% (n=35) vs -20% (n=32) placebo @ 12wk0.3% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-35.7% (n=34) vs -20% (n=32) placebo @ 12wk1.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-33.7% (n=37) vs -20% (n=32) placebo @ 12wk3.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-25.94% (n=37) vs -12.76% (n=36) placebo @ 14wk0.1% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-8.58% (n=37) vs -12.76% (n=36) placebo @ 14wk0.3% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-23.14% (n=36) vs -12.76% (n=36) placebo @ 14wk1.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-30.07% (n=37) vs -12.76% (n=36) placebo @ 14wk3.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-14.18% (n=36) vs -12.76% (n=36) placebo @ 14wk0.3% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-27.56% (n=35) vs -12.76% (n=36) placebo @ 14wk1.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-19.74% (n=38) vs -12.76% (n=36) placebo @ 14wk3.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-23.01% (n=37) vs -4.72% (n=36) placebo @ 16wk0.1% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-9% (n=37) vs -4.72% (n=36) placebo @ 16wk0.3% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-29.24% (n=36) vs -4.72% (n=36) placebo @ 16wk1.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-27.17% (n=37) vs -4.72% (n=36) placebo @ 16wk3.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-9.99% (n=36) vs -4.72% (n=36) placebo @ 16wk0.3% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-24.09% (n=35) vs -4.72% (n=36) placebo @ 16wk1.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
-21.12% (n=38) vs -4.72% (n=36) placebo @ 16wk3.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
sPGA 0/1 10.3% (n=29) vs 6.9% (n=29) placebo @ 12wk0.1% QD
responder rate · % of participants
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
show 62 more results
15.4% (n=26) vs 6.9% (n=29) placebo @ 12wk0.3% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
10.3% (n=29) vs 6.9% (n=29) placebo @ 12wk1.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
21.4% (n=28) vs 6.9% (n=29) placebo @ 12wk3.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
20.8% (n=24) vs 6.9% (n=29) placebo @ 12wk0.3% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
27.6% (n=29) vs 6.9% (n=29) placebo @ 12wk1.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
17.9% (n=28) vs 6.9% (n=29) placebo @ 12wk3.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
2.7% (n=37) vs 2.8% (n=36) placebo @ 1wk0.1% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
2.7% (n=37) vs 2.8% (n=36) placebo @ 1wk0.3% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
0% (n=36) vs 2.8% (n=36) placebo @ 1wk1.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
0% (n=37) vs 2.8% (n=36) placebo @ 1wk3.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
0% (n=36) vs 2.8% (n=36) placebo @ 1wk0.3% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
5.7% (n=35) vs 2.8% (n=36) placebo @ 1wk1.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
5.3% (n=38) vs 2.8% (n=36) placebo @ 1wk3.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
0% (n=37) vs 2.8% (n=36) placebo @ 2wk0.1% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
0% (n=37) vs 2.8% (n=36) placebo @ 2wk0.3% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
2.8% (n=36) vs 2.8% (n=36) placebo @ 2wk1.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
2.7% (n=37) vs 2.8% (n=36) placebo @ 2wk3.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
0% (n=36) vs 2.8% (n=36) placebo @ 2wk0.3% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
5.7% (n=35) vs 2.8% (n=36) placebo @ 2wk1.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
10.5% (n=38) vs 2.8% (n=36) placebo @ 2wk3.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
5.4% (n=37) vs 5.6% (n=36) placebo @ 4wk0.1% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
0% (n=37) vs 5.6% (n=36) placebo @ 4wk0.3% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
5.6% (n=36) vs 5.6% (n=36) placebo @ 4wk1.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
5.4% (n=37) vs 5.6% (n=36) placebo @ 4wk3.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
8.3% (n=36) vs 5.6% (n=36) placebo @ 4wk0.3% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
11.4% (n=35) vs 5.6% (n=36) placebo @ 4wk1.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
21.1% (n=38) vs 5.6% (n=36) placebo @ 4wk3.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
5.4% (n=37) vs 8.3% (n=36) placebo @ 6wk0.1% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
2.7% (n=37) vs 8.3% (n=36) placebo @ 6wk0.3% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
8.3% (n=36) vs 8.3% (n=36) placebo @ 6wk1.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
13.5% (n=37) vs 8.3% (n=36) placebo @ 6wk3.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
8.3% (n=36) vs 8.3% (n=36) placebo @ 6wk0.3% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
5.7% (n=35) vs 8.3% (n=36) placebo @ 6wk1.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
13.2% (n=38) vs 8.3% (n=36) placebo @ 6wk3.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
5.4% (n=37) vs 11.1% (n=36) placebo @ 8wk0.1% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
5.4% (n=37) vs 11.1% (n=36) placebo @ 8wk0.3% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
2.8% (n=36) vs 11.1% (n=36) placebo @ 8wk1.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
10.8% (n=37) vs 11.1% (n=36) placebo @ 8wk3.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
13.9% (n=36) vs 11.1% (n=36) placebo @ 8wk0.3% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
5.7% (n=35) vs 11.1% (n=36) placebo @ 8wk1.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
18.4% (n=38) vs 11.1% (n=36) placebo @ 8wk3.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
5.4% (n=37) vs 8.3% (n=36) placebo @ 10wk0.1% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
8.1% (n=37) vs 8.3% (n=36) placebo @ 10wk0.3% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
8.3% (n=36) vs 8.3% (n=36) placebo @ 10wk1.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
16.2% (n=37) vs 8.3% (n=36) placebo @ 10wk3.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
16.7% (n=36) vs 8.3% (n=36) placebo @ 10wk0.3% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
8.6% (n=35) vs 8.3% (n=36) placebo @ 10wk1.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
13.2% (n=38) vs 8.3% (n=36) placebo @ 10wk3.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
13.5% (n=37) vs 2.8% (n=36) placebo @ 14wk0.1% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
5.6% (n=37) vs 2.8% (n=36) placebo @ 14wk0.3% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
8.6% (n=36) vs 2.8% (n=36) placebo @ 14wk1.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
13.5% (n=37) vs 2.8% (n=36) placebo @ 14wk3.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
8.8% (n=36) vs 2.8% (n=36) placebo @ 14wk0.3% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
11.8% (n=35) vs 2.8% (n=36) placebo @ 14wk1.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
8.1% (n=38) vs 2.8% (n=36) placebo @ 14wk3.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
11.4% (n=37) vs 5.6% (n=36) placebo @ 16wk0.1% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
8.6% (n=37) vs 5.6% (n=36) placebo @ 16wk0.3% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
14.3% (n=36) vs 5.6% (n=36) placebo @ 16wk1.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
16.2% (n=37) vs 5.6% (n=36) placebo @ 16wk3.0% QD
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
14.7% (n=36) vs 5.6% (n=36) placebo @ 16wk0.3% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
11.8% (n=35) vs 5.6% (n=36) placebo @ 16wk1.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2
16.2% (n=38) vs 5.6% (n=36) placebo @ 16wk3.0% BID
NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: brepocitinib's landscape · Girocitinib's landscape